<DOC>
	<DOC>NCT02176382</DOC>
	<brief_summary>The aim of the study is to assess the effect of an antiresorptive medication in combination with standard dose or alternate dose teriparatide.</brief_summary>
	<brief_title>Denosumab and Teriparatide Study (DATA-2)</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>women aged 45+ postmenopausal osteoporotic with high risk of fracture no significant previous use of bone health modifying treatments</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>